Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
19-1XX CAR T cells
- Development stage
- Unknown
- Lead developer
- Memorial Sloan Kettering Cancer Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
19-1XX CAR T cells (formally 19(T2)28z-1XX) is an autologous CAR T-cell therapy developed by Memorial Sloan Kettering Cancer Center (MSK) targeting CD19. It features a novel 1XX CAR construct designed with calibrated signaling by mutating two of the three immunoreceptor tyrosine-based activation motifs (ITAMs) in the CD3ζ domain, leaving only the proximal ITAM functional. This modification aims to reduce T-cell exhaustion and enhance persistence compared to conventional CD19 CAR T cells. In clinical trials for relapsed or refractory large B-cell lymphoma, it has demonstrated high response rates at significantly lower doses than currently approved CAR T products. The 1XX technology has been licensed to several biopharmaceutical companies, including Atara Biotherapeutics and Takeda.
- Other names
- 19-1XX CAR T cells19(T2)28z-1XX
02
Targets
CD19 (B lymphocyte antigen CD19)CD28 (Cluster of Differentiation 28)
Beyond the preview
Go deeper on 19-1XX CAR T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 19-1XX CAR T cells.